Trial Profile
A Single-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY2541546 in Healthy Postmenopausal Women
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Blosozumab (Primary) ; Blosozumab (Primary)
- Indications Postmenopausal osteoporosis
- Focus Adverse reactions; Biomarker
- Sponsors Eli Lilly and Company
- 28 Dec 2012 New source identified and integrated: ClinicalTrials.gov record.
- 28 Oct 2012 New trial record
- 16 Oct 2012 Results presented at the 34th Annual Meeting of the American Society for Bone and Mineral Research.